Ikarian Capital’s Kyntra Bio KYNB Stock Holding History

Ikarian Capital’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-111	Closed	-$2.39K	–	150
2023 Q3	$2.39K	Sell	111 -9,026	-99%	-$354K	﹤0.01%	139
2023 Q2	$617K	Buy	+9,137	New	+$3.78M	0.1%	95

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ikarian Capital's KYNB Position: Q4 2023 in Review

Ikarian Capital sold out of Kyntra Bio (KYNB) in Q4 2023, closing a stake of 111 shares — an estimated $2.39K sold.

Ikarian Capital first reported a position in KYNB in Q2 2023 and held it in 2 quarters. The position peaked at $617K in Q2 2023. 100 funds tracked by Wall St. Rank hold KYNB as of Q4 2023.

Ikarian Capital reported no remaining Kyntra Bio position as of Q4 2023 after selling out during the quarter.
Ikarian Capital sold 111 Kyntra Bio shares in Q4 2023, an estimated $2.39K.
Ikarian Capital first reported a position in Kyntra Bio in Q2 2023 and held it in 2 quarters.
Ikarian Capital's Kyntra Bio position peaked at $617K in Q2 2023.
100 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2023.

Based on Ikarian Capital's 13F filing for Q4 2023, filed 14 Feb 2024.